Section Menu

Research

Research programs in the Division of Cardiovascular Medicine are among the most robust in the Health System and including more than 140 active clinical, translational and basic research projects. This work is funded by an equally wide breadth of resources including the National Institutes of health, pharmaceutical and device industry, philanthropy and other sources. Our clinicians and researchers are highly visible, routinely presenting at regional, national, and international society meetings and produced more than 240 manuscripts and abstracts in 2019.

Highlights of the cardiovascular research program include:

National Heart, Lung and Blood Institute-funded research

The Division is home to several investigators with long track records of NIH funding ranging from mechanistic studies in model systems to translational science in humans, and even including cutting edge clinical trials.
Improving attendance to cardiac rehabilitation trial (iATTEND, Principal Investigator: Steven Keteyian Ph.D.)

  • Impact of race and genetic factors on beta-blocker effectiveness in heart failure (Principal Investigator: David E. Lanfear, M.D. M.S.)
  • Cardiac energy metabolism in heart failure (Principal Investigator: Hani Sabbah, Ph.D.)
  • Plasma Metabolomics and Myocardial Energetics in Heart Failure (Principal Investigators: David E. Lanfear, M.D., M.S. and Hani Sabbah PhD)
  • Racial Disparity in Heart Failure Clinical Outcomes and Angiotensin system blockade (Principal Investigator: Jasmine Luzum, Ph.D. Pharm.D.)
  • GRAHF-2: Genomic Analysis of Enhanced Response to Heart Failure Therapy in African Americans (enrolling site)
  • Improving attendance to cardiac rehabilitation trial (iATTEND, Principal Investigator: Steven Keteyian Ph.D.)

The Cardiovascular Research Laboratory

Hani Sabbah PhD

The Division’s Cardiovascular Research Laboratory (CRL), Directed by Dr. Hani N. Sabbah, PhD, conducts research into the causes and novel treatments of heart failure. With a focus on basic and translational research, investigators are concerned with understanding the mechanisms leading to progression of heart failure, ventricular remodeling, and reversing this process using drugs and devices. Ongoing research explores energy production in the failing heart, signaling mechanisms that foster dysfunction of cardiac muscle cells, ion channels and arrhythmias. Beyond molecular biology and biochemistry, the CRL performs pre-clinical testing in model systems to develop and test novel drugs and devices for heart failure.

Clinical Trials

The Cardiovascular Division carries out an amazing array of active clinical trial work across the spectrum of Cardiology. The Division maintains central infrastructure and oversight for clinical trials operations along with functional trial groups that operate within each of the sections.

  • Advanced Heart Failure Section Clinical Trials
    If interested in the trials below, please contact Kelsey Neaton at 313-829-3570.
    • ARIES-HF- Prospective, randomized, double blinded, placebo controlled clinical investigation of advanced heart failure patients with the HM3 with two antithrombotic regimes, vitamin K antagonist with aspirin vs vitamin K antagonist with placebo. (PI- Jennifer Cowger)
    • CHIEF-HF- Canagliflozin:Impact on Health Status, Quality of Life, and Functional Status of Heart Failure (PI- David Lanfear)
    • FINEARTS-HF- Multicenter, randomized, double blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and morality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction >40% (PI- Yelena Selektor)
    • GUIDE-HF- Single Arm prospective multicenter clinical trial of the CardioMEMS HF System. (PI- Gillian Grafton)
    • MANAGE-HF- Study the effectiveness of two patient centered applications with contextual just in time interventions for Heart Failure. The two interventions will target self-management during clinical worsening and dietary sodium intake with the goal of improving the health status of patients (PI- Jennifer Cowger)
    • METEORIC HF- A double blind randomized, placebo controlled Multi-Centered Study to Assess the Effects of Omecamtive Mecarbil on Exercise Capacity for in Subjects with heart failure with reduced EF (PI- Bashar Hannawi)
    • PARAGLIDE-HF- Multi Center randomized double blind parallel group, double dummy, parallel group, active controlled study to evaluate the effect of sacubitril/valsartan vs valsartan on changes in NT-proBNP and outcomes, safety, and tolerability in HFpEF with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization and initiated in hospital or within 30 days post discharge. (PI- Yelena Selektor)
    • SHORE- Surveillance HeartCare Outcomes Registry (PI- Cristina Tita)
    • TRANSFORM- Pragmatic trial of Torsemide vs Furosemide (PI- Gillian Grafton)
    • PROACTIVE-HF – A prospective, multi-center, randomized controlled, single blind clinical trial evaluating the safety and efficacy of the Cordella Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients. (PI- Jennifer Cowger)
  • Structural Heart Disease Clinical Trials
    If interested in the trials below, please contact Ardit Kacorri at 313-916-7452.
    • CLASP II TR- Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial: A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation. (PI: William O’Neill)
    • ENCIRCLE- High-Risk Trial SAPIEN M3 System TransCatheter MItral Valve ReplaCement via TransseptaL AccEss (PI: William O’Neill)
    • Early Feasibility Study of the Edwards Lifesciences Edwards M3 System for the Treatment of Severe Mitral Regurgitation (PI: William O’Neill)
    • TRISCEND Study - Edwards Transcatheter Tricuspid Valve Replacement: Investigation of Safety and Clinical Efficacy using a Novel Device (PI: William O’Neill)
    • TRISCEND II Pivotal Trial: Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device (PI: William O’Neill)
    • SAPIEN 3 Ultra US Post-Market Registry (PI: William O’Neill)
    • SAVE- Supra-Annular vs. annular ValvEs for Small Annuli (SAVE) (PI: Marvin Eng)

    If interested in the following trials, please contact Samantha Henry 313-916-4475.
    • CLASP IID - Edwards PASCAL Transcatheter Mitral Valve Repair System Pivotal Clinical Trial: A prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Mitral Valve Repair System compared to Abbott MitraClip in patients with degenerative mitral regurgitation (DMR). (PI: William O’Neill)
    • PROJECT TITLE - Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients with AsYmptomatic Severe Aortic Stenosis (PI: William O’Neill)
    • PROJECT TITLE - Role and Prognostic Utility of Biomarkers in the Clinical Assessment of Patients Before and After Transcatheter Valvular Interventions: Observational study. (PI: Tiberio Frisoli)

    If interested in the trials below, please contact Ashish Solanki 313-916-3571.
    • ACURATE IDE - Transcatheter Replacement of Stenotic Aortic Valve through implantation of ACURATE in Subjects InDicatEd for TAVR (PI: William O’Neill)
    • AMPLATZERTM PFO Occluder Post Approval Study (PI: William O’Neill)
    • SUMMIT - Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (PI: Marvin Eng):
    • WATCHMAN for TAVR- Watchman for Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement (PI: William O’Neill)
    If you are interested in the trial below, please contact Dr. Frisoli at 313-916-3875.
    • Conduction Disease after Transcatheter Aortic Valve Replacement (PI: Tiberio Frisoli)
  • Preventive Cardiology Unit Clinical Trials
  • Electrophysiology Section Clinical Trials
    If interested in the trials below, please contact Briita Wanhala at 313-916-9575.
    • OPTION - Comparison of Anticoagulation with Left Atrial Appendage Closure after AF Ablation (PI- Arfaat Khan)
    • ULTRA HFIB - Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation (PI- Marc Lahiri)
    • SOLVE CRT - Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (PI- Marc Lahiri)
    • ASAP TOO - Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (PI- Marc Lahiri)
    • APPRAISE ATP - Assessment of Primary Prevention Patients Receiving An ICD – Systematic Evaluation of ATP (PI- Gurjit Singh)
    • PREEMPT-HF - PREcision Event Monitoring of PatienTs with Heart Failure using HeartLogic (PI-Gurjit Singh)
  • Cardiac Catheterization Laboratory Clinical Trials
    If you are interested in the trials below, please contact Margaret Fox at 313-916-1879 or Melanee Schimmel at 313-916-7614.
    • Progress CTO Registry - Multi center Registry of Chronic total Occlusion Interventions (PI-Khaldoon Alaswad)
    • Theme Registry -Tandem Heart Experiences and Methods (PI-Khaldoon Alaswad)
    • Cardiamp Heart Failure Trial - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the Cardiamp Cell Therapy in Patients with Post Myocardial Infarction Heart Failure (PI- Gerald Koenig)
    • Eclipse Trial - Evaluation of Treatment Strategies for Severe Calclfic Coronary Arteries: Orbital Atherectomy vs Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting Stents (PI-Khaldoon Alaswad)
    • Flash Trial- FlowTriever All-Comer Registry for Patient Safety and Hemodynamics (PI- Gerald Koenig)
    • CTO-PCI Study - Chronic Total Occlusion Percutaneous Coronary Intervention (PI-Khaldoon Alaswad)
    • Radiance II Pivotal Study - A Study of the ReCor Medical Paradise System in Stage II Hypertension (PI- Gerald Koenig)
    • DTU Pivotal Study - Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction. (PI- Gerald Koenig)

Clinical Registries

The Cardiovascular Division maintains a large number of observational registries and cohort studies in order to continuously learn from the division’s extensive and innovative clinical activities.

  • FIT-CPX- The Henry Ford Hospital Cardiopulmonary Exercise Testing Project
  • Henry Ford STEMI Registry
  • Henry Ford Genomic Registry
  • Henry Ford SPECT Registry
  • Henry Ford Coronary CTA database
  • Advanced cardiac imaging consortium Michigan CTA database
  • Henry Ford Cardiac MRI database
  • HF-Action- Exercise training in Heart Failure
  • Multicenter cardiac sarcoidosis registry
  • Retrospective HF and MI databases utilizing Corporate Data Store
  • National Cardiovascular Data Registry
  • Blue Cross Blue Shield of Michigan BMC2-PCI Registry - Percutaneous coronary intervention registry
  • STS/ACC TVT Registry - Transcatheter valve replacement and repair procedures
  • ACC LAAO Registry- covers Left Atrial Appendage Closure
  • TOPAS-TAVI- Transcatheter Aortic Valve Implantation in Patients with Low-Flow, Low Gradient Aortic Stenosis (Truly or Pseudo Severe Aortic Valve Stenosis). A Prospective Multicenter Registry.
  • PROGRESS CTO REGISTRY- Multi center Registry of Chronic total Occlusion Interventions
  • EAGLE Registry- Close Chested Epicardial Ligation of the Left Atrial Appendage in Atrial Fibrillation Patients Registry: A Multicenter Prospective Observational Cohort
  • IRAD registry - aortic dissection registry
  • Michigan Anticoagulation Quality Improvement Initiative
  • TRIUMPH registry- Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patient’s Health Status Registry
  • THEME Registry- enrolling patients who receive TandemLife devices
  • USPella Registry- enrolling patients who receive Impella devices
  • MITRAL Registry- mitral valve in valve, valve in ring, valve in MAC registry for transcatheter mitral valve implantation using Sapien valves in the mitral position
  • POMME-Registry
  • Amplatzer PFO Closure: Post-approval registry for Amplatzer PFO devices
  • NCDR: TVT and LAA-O in Structural heart
  • CVAD registry- Shock and Impella
  • INTERMACS- InterAgency Registry of Assisted Circ Support
  • IMACS: ISHLT Mechanically Assisted Circulatory Support Registry
  • MCSRN: Mechanical Circulatory Support Research Network
  • Preventive Cardiology Outcomes (PRECO) database
  • OPTIMUM Trial: Outcomes of Percutaneous Revascularization for Management of Surgically Ineligible Patients with Multivessel of Left Main Coronary Artery Disease: A Prospective Registry.
  • US Caval Valve Registry
  • Michigan TAVR Registry
X

Cookie Consent

We use cookies to improve your website experience. By using this site, you agree to our Terms of Use. Read our Internet Privacy Statement  to learn what information we collect and how we use it.

Accept all
Dismiss